SlideShare a Scribd company logo
Joseph Priestly – discovers N2O in 1773
Crawford W. Long – 1842. Country Dr. in Georgia first used ether
for neck surgery. Did not publicize.
Tried to claim credit after Morton’s demonstration but…
Important lesson learned – if you don’t publish it, it didn’t
happen.
Sir Humphrey Davy – experimented with N2O, reported loss of
pain, euphoria
Horace Wells 1844. Demonstrated N2O for tooth extraction –
deemed a failure because patient “reacted”.
History of Anesthesia
WORLD ANAESTHESIA DAY
16TH OCT 1846
W.T.G.MORTON
John Collin Warren
Gilbert Abortt
How do Inhalational Anesthetics
Work?
Surprisingly, the mechanism of action is still largely unknown.
"Anesthetics have been used for 160 years, and
how they work is one of the great mysteries of
neuroscience," James Sonner, M.D. (UCSF)
Lipid Theory
Membrane Stabilization Theory
Promiscuous Receptor Agonist Theory:
Anesthetics may act at GABA receptors, NMDA receptors, other receptors
Modifying functions of ION CHANNELS (opening of
inhibitory ion channels (Cl- or K+) and closing of excitatory ion channels (Na+)
 Speed(extremely rapid action and fast
changes in level of anesthesia)
 Faster turnover/recovery times
 Route of administration- lungs (get 100%
of cardiac output)
 Margin of safety
The main target of inhalation anesthetics is
the brain.
Goal
To develop and maintain a satisfactory
partial pressure or tension of anesthetic at
the site of anesthetic action in brain.
Alveolar concentration of anesthetic gas is
indirectly reflects brain concentration.
PA PB
 Vaporizer
 Breathing Circuit
 Alveoli (lungs)
 Arterial Blood
 Tissues (VRG [brain], MUS,FAT)
 Venous blood (coming back to lungs)
 Alveoli (lungs, again)
 Breathing Circuit (to be rebreathed)
Time constant
Uptake and distribution of anesthetic
gases
FI
FA
FD
MAC
Brain Partial pressure
drives depth of
anesthesia
Equilibrates
Ventilation
λB/G
CO
PA - PV
λT/B
Tissue blood flow
[Parterial - PTissue]
1
2
FA/FI
Concentration and
second gas effects
Time constant
VRG
 The absorption phase is usually called -
uptake
 The metabolic phase is usually called -
biotransformation
 The excretion phase is usually called –
elimination.
 lowering of drug concentration in one compartment by
delivery into another compartment is called
redistribution
 Partial Pressure
-the pressure a gas exerts- proportional
its fractional mass
 Additive
Patm = PO2 + PN2
=160mmHg + 600mmHg
= 760mmHg
 Ptotal= Pgas1+ Pgas2+ ….+Pgas N
(Dalton’s law)
Same pressure each gas would have if
IT ALONE occupied the same volume
 Pressure- gas phase
 Concentration – amount of gas
dissolved in a solution.
 Solubility = volume of gas
volume of liquid
(at standard temperature)
What is “ PARTIAL PRESSURE OF GAS” in
solution?
Reflects a “force” of gas to escape
out of solution ( think of CO2 in a bottle
of soda)
Gasses equilibrate based on partial pressures, not on
concentrations
By convention, we use fractional concentration(F) instead
of partial pressure(P)
Ex: We could say FO2= 21% instead of PO2= 160 mmHg
Thus, F is proportional to P
Physiologically, our body needs the partial
pressure, not the fractional concentration!!!
Henry”s law: Cg = k Pg
Cg - is concentration of gas in solution
k - is a solubility constant
Pg - is the partial pressure of the gas
 Physiologically,
Anesthetic gases work based on partial
pressure in the brain, not fractional
concentration
Anesthetic gases work based on partial
pressure in the brain, not fractional
concentration !
The vaporizers are calibrated to deliver a set
partial pressure, NOT a set fractional
concentration!
SEVO vaporizer only delivers 1% sevoflurane
when P atm= 760mmHg.
But it will always deliver(appr) the correct partial
pressure of sevoflurane at any altitude.
True for ALL vaporizers EXCEPT DESFLURANE
Getting agent from the anesthesia
machine into the brain so the patient goes to sleep!!!
 Goal: achieve “steady state” of anesthetic
partial pressures throughout the system
 Vaporizer adds agent to the fresh gas flow at a
fixed concentration
 Fresh gas mixes with circuit gas (bag, tubing
canister, piping), dilutes concentration of agent
 Compartments equilibrate and concentration of
agent in the circuit rises
 Fractional concentration of agent leaving the
circuit is Fi (fraction inspired)
 Fractional concentration of agent in the lungs is FA
(fraction alveolar)
 Initially, FA/Fi = 0 because Fa is a 0
No agent in the lungs yet
 These compartments will also equilibrate over time
You will be at EQ when FA=Fi, or FA/Fi=1
Fast induction is defined as FA/Fi → 1 quickly
ANAESTHESIC
MACHINE BREATHING
CIRCUIT
LUNGS
ARTERIAL
BLOOD
VENOUS
BLOOD
BRAIN
FGF
FI
FA
Fa
Path of anesthetic
FFGO -is the fraction of inspired
anesthetic in the gas leaving the fresh
gas outlet.
T - is time.
τ - is a time constant.
The time constant is simply the
volume or “capacity” of the circuit
(VC) divided by the fresh gas flow
(FGF) or τ = VC/FGF.
Concentration in the circuit (FI) will
rise according to first-order kinetics:
Concentration of (FA) will rise
analogous to Fi
FA -is the alveolar concentration
T - is time.
τ -is a time constant.
The time constant for raise of FA
concentration and equals FRC/VA
FRC-functional residual capacity
VA- minute ventilation
 The time required for flow through a
container to equal the capacity of the
container.
TC is volume (capacity)/flow.
 The time constant for the lungs is
FRC/Valveolar.
 The time constant for the anesthesia circuit
is circuit capacity/FGF.
 If 10 liter box is initially filled with oxygen and 5
l/min of nitrogen flow into box then,
 TC is volume (capacity)/flow.
 TC = 10 / 5 = 2 minutes ( 1 Time Constant)
 So, the nitrogen concentration at end of 2
minutes is 63%.
O2 10 Lt
5
Lt/min
2 Mts 4 Mts 6 Mts 8 Mts
63% 86% 95% 98%
N2
Time Constant at Lungs
Time Constants and Brain Equilibration
Time constant Brain Equilibration time
Isoflurane 3-4 mins 10-15 mins
Sevoflurane 2 mins 6 mins
Desflurane 2 mins 6 mins
Nitrous Oxide 2 mins 6 mins
equilibration with any tissue takes 3 time constants
a) The inspired concentration (FI)
Inspired concentration - FA/FI
b) The alveolar ventilation (Valveolar)
- Minute alveolar ventilation - FA/FI
- Larger the FRC - slows raise of alveolar
concentration
c) The time constant
d) Anesthetic uptake by the blood
e) The concentration and second gas effects
1) Fresh Gas Flow rate:
↑ FGF → ↑ speed of induction &
recovery.
2) Volume of breathing circuit
(apparatus dead space): incr.
↑volume → slower induction
(dilution of anesthetic gases.)
3) Absorption by the breathing
circuit: rubber tubing absorbs ˃
plastic & silicon.
Increase in
Minute alveolar ventilation
Increases FA/FI
The change is greatest for
more soluble anesthetics
methoxyflurane - increases by 75%
isoflurane - by 18%
desflurane - by only 6%.
negative feedback that results
from respiratory depression
high ventilation → rapid
induction → hypoventilation
Increase FA/FI Decrease FA/FI
Comment
Low blood solubility High blood solubility
As the blood solubility
decreases, the rate of rise in
FA/FI increases.
Low cardiac output High cardiac output
The lower the cardiac
output, the faster the rate of
rise in FA/FI
High minute ventilation Low minute ventilation
The higher the minute
ventilation, the faster the
rate of rise in FA/FI
Factors that Increase or Decrease the Rate of Rise of F /F
Uptake from the lung = Blood solubility x Cardiac Output x [PA-PV]
Bar. pressure
50%O2
50%N2O
2Lt
2Lt
4Lt
33%N2O
66%O2
3Lt
2Lt
1Lt
Uptake of half
of the N2O
38%N2O
62%O2
1Lt of N2O
1 Lt
50%O2 + 50%N2O
Ventilation Effect Inspired Gas
1.5Lt
4Lt
2.5Lt
The higher the inspired
concentration, the more rapid the
rise in alveol. concentration
.
The concentration effect is only significant for gases present in high
concentrations (e.g. nitrous).
.
Two components:
1.the concentrating effect
2.an augmented gas inflow effect
Administration of 70% nitrous oxide
produces a more rapid rise in the
FA/FI ratio of nitrous oxide than
administration of 10% nitrous oxide
The FA/FI ratio for 0.5% halothane
rises more rapidly when given with
70% nitrous oxide than when given
with 10% nitrous oxide.
Concentration effect
Second gas effect
Factors raising the alveolar concentration (FA/FI )
a) The inspired concentration (FI)
b) The alveolar ventilation (Valveolar)
c) The time constant
d) Anesthetic uptake by the blood
e) The concentration and second gas effects
Factors determining uptake by blood
A. Solubility in blood
B. Cardiac Output
C. The mixed venous anesthetic concentration
d. Tissue uptake of anesthetic
Uptake from the lung = Blood solubility x Cardiac Output x [PA-PV]
Barometric pressure
U Lung = λB/G x Q x ((PA-Pvenous)
Barometric pressure
Fick equation
λB/G - blood:gas partition coefficient
Q - cardiac output
PA - alveolar partial pressure of anesthetic
Pv - mixed venous partial pressure of anesthetic
PB is barometric pressure.
 Solubility is defined in terms of the partition
coefficient
 Partition coefficient is the ratio of the
amount of substance present in one phase
compared with another, the two phases
being of equal volume and in equilibrium
[λB/G = CB ]
CG
Gas
Blood
Partition Coefficient = Ratio of Concentration
Concentrations Equilibirates
Partial pressure Equalize
CG =CB
PG = PB
Halothane
λB/G = CB = 2.5 = 2.5
CG 1
Equal volume
Partial pressures are equal but concentrations are not !!!
Blood has 50 balls of halothane/ml Gas has 20 balls of halothane / ml
Halothane blood / gas partition coefficient = 2.5
No net diffusion when
partial pressures are
equal.
Blood has 8 balls / ml desflurane Gaseous desflurane has 20 balls /ml
Desflurane blood / gas partition coefficient = 0.42
No net diffusion when
partial pressures are
equal.
 Higher solubility (λB/G>1)= more agent in the
blood and less in the gas phase.
 A lower solubility (λB/G<1)= less agent in the
blood and more in the gas phase.
 Other partition coefficients:
-Brain:Blood, Muscle:Blood, Fat:Blood
(describe movement of gas from one
environment to another)
Blood-Gas
Brain-
Blood
Liver-
Blood
Kidney-
Blood
Muscle-
Blood
Fat-
Blood
Desflurane 0.42 1.3 1.4 1.0 2.0 27
Nitrous oxide 0.47 1.1 0.8 — 1.2 2.3
Sevoflurane 0.65 1.7 1.8 1.2 3.1 48
Isoflurane 1.17 1.6 1.8 1.2 2.9 45
Enflurane 1.8 1.4 2.1 — 1.7 36
Halothane 2.4 1.9 2.1 1.2 3.4 51
Diethyl ether 12 2.0 1.9 0.9 1.3 5
Methoxyfluran
e
15 1.4 2.0 0.9 1.6 38
PARTITION CO-EFFICIENT
The more soluble the anesthetic
The more drug will be taken up
by the blood
The slower the rise in alveolar
concentration
15
1.4
0.65
0.47
Poor solubility Rapid induction
High solubility Slow induction
Greater the cardiac output
The more drug will be taken up
by the blood
The slower the rise in alveolar
concentration
Cardiac output is lowered
cerebral circulation
less maintained (shock)
Induction Induction
slower rapid
An increase in CO from 2 to 18 L/min
will decrease the alveolar anesthetic
concentration by augmenting
uptake, thereby slowing the rise of the
FA/FI ratio.
B.Cardiac Output(Perfusion Effects)
More soluble anesthetics (halothane)
- effect is more prominent
Positive feedback - as inspired
concentration increases, greater
cardiovascular depression reduces
anesthetic uptake and actually
increases the rate of rise of FA/FI.
The difference between partial pressure in the alveoli and that in
venous blood
Partial pressure in venous blood depends on tissue uptake of
anesthetic
At equilibrium, (no tissue uptake)
The venous partial pressure = arterial partial pressure =
alveolar partial pressure
PA – PV = 0
Rate of rise of the mixed venous concentration depends on the
tissue uptake of the anesthetic
AT EQUILIBRIUM
Notissueuptake
PA
PV
PA – PV = 0
PA = PV
FA/FI
FAT
VRG
MG
4-8mts
2-6Hrs
3-4 days
1. The tissue/blood partition coefficient (tissue solubility)
2. The tissue blood flow.
3. The tissue anesthetic concentration
Tissue Uptake = Tissue solubility x Tissue blood flow x [Parterial - PTissue]
Atmospheric pressure
Gas
Blood
Tissue
Concentrations Equilibirates
Partial pressure Equalize
CG =CB = CT
PG = PB = PT
Equal volume
Brain has 19 balls halothane / ml Blood has 10 balls halothane / ml
Halothane brain / blood partition coefficient = 1.9
No net diffusion
when partial
pressures are
equal.
Brain has 11 balls N2O / ml Blood has 10 balls N2O / ml
N2O brain / blood partition coefficient = 1.1
No net diffusion
when partial
pressures are
equal.
Blood-Gas
Brain-
Blood
Liver-
Blood
Kidney-
Blood
Muscle-
Blood
Fat-
Blood
Desflurane 0.42 1.3 1.4 1.0 2.0 27
Nitrous oxide 0.47 1.1 0.8 — 1.2 2.3
Sevoflurane 0.65 1.7 1.8 1.2 3.1 48
Isoflurane 1.17 1.6 1.8 1.2 2.9 45
Enflurane 1.8 1.4 2.1 — 1.7 36
Halothane 2.4 1.9 2.1 1.2 3.4 51
Diethyl ether 12 2.0 1.9 0.9 1.3 5
Methoxyfluran
e
15 1.4 2.0 0.9 1.6 38
PARTITION CO-EFFICIENT
The rate of rise in tissue anesthetic concentration is
proportional to tissue blood flow and inversely
proportional to the tissue capacity.
The tissue capacity = tissue solubility х tissue volume
Just as discussed for the lungs, the tissues have a time
constant too:
Time Constant = Tissue solubility x Volume
Flow
Equilibration of
the VRG complete
in 4 to 8 minutes
After 8 minutes,
the Muscle group
(MG) determines
most of uptake.
Once MG
equilibration is
complete Fat
group (FG)
determines the
uptake
Two important characteristics of
Inhalational anesthetics which govern
the anesthesia are :
Solubility in the blood
(blood : gas partition co-efficient)
Solubility in the fat
(oil : gas partition co-efficient)
 It indicates the amount of gas that is
soluble in oil phase.
 It is a measure of lipid solubility of
anesthetic.
 It is a measure of anesthetic potency
Higher the lipid solubility – potent anesthetic.
(e.g., halothane)
Meyer – Overton Rule
Anesthetic potency
correlates with lipid
solubility
Holds true across species
Because inhalation agents act through the lipid-rich
CNS cells, anesthetic potency increases with
lipid solubility.
OIL GAS PARTITION CO-EFFICIENT
Higher the Oil: Gas Partition
Co-efficient lower the MAC .
E.g., Halothane
1.4 220
0.8
Inhalation
Anesthetic
MAC value % Oil:Gas partition
Co
Nitrous oxide 104 1.4
Desflurane 6.6 19
Sevoflurane 1.8 47
Isoflurane 1.17 91
Halothane 0.75 220
Oil:Gas Partition Co-efficient and
MAC
 At EQ:PA(alveoli)= Pblood =PCNS
Rapid transfer of gases:
alveoli > blood > CNS
 F is proportional to P, so
1% SEV in the alveoli = 1% SEV in the CNS
At EQ, if you know PA of a gas, then
you know PCNS
Recovery from anesthesia, like induction, depends on:
 anesthetic solubility- is the primary determinant of
the rate of fall of FA
 cardiac output
 minute ventilation
Loss of inhaled anesthetics via skin, gastrointestinal
viscera and the pleura are insignificant
The greater the solubility of inhaled anesthetic, the
larger the capacity for absorption in the bloodstream
and tissues.
 The “reservoir” of anesthetic in the body at
the end of administration depends on:
1. Tissue solubility (which determines the capacity)
2. The dose
3. Duration of anesthetic (which determine how
much of that capacity is filled).
Low solubility→Rapid recovery
Desflurane>Sevoflurane>Isoflurane
Recovery from anesthesia, or
“washout,” is usually
expressed as the ratio of
expired fractional
concentration of anesthetic
(FA) to the expired
concentration at time zero
(FA0) when the anesthetic was
discontinued (or FA/FA0).
During the 120-minute period after ending the
anesthetic delivery, the elimination of sevoflurane and
desflurane is 2 to 2.5 times faster than isoflurane or
halothane
The longer the duration of a highly soluble anesthetic, the greater
the reservoir of anesthetic in the body, and the higher the curve
seen in the right half( slow recovery)
INDUCTION RECOVERY
Induction can be accelerated by
Over Pressure( which offset
solubility and uptake)
The inspired concentration
cannot be reduced below zero
All the tissues initially have the
same anesthetic partial
pressure—zero
On recovery, the tissue partial
pressures are variable
100%
60% 10%
0% Recovery
 As long as an arterial-to-tissue partial pressure gradient
exists, muscle and fat will absorb anesthetic(especially
fat).
 After discontinuation of anesthesia, muscle and fat
may continue to absorb anesthetic, even hours later.
 The redistribution continues until blood/alveolar
anesthetic partial pressure falls below tissue partial
pressure.
1. Increased solubility slows recovery
2. Increasing ventilation may help the recovery
from potent agents
3. Prolonged anesthesia delays recovery
4. There is no concentration effect on
emergence
Diffusion hypoxia
Also called as Fink effect.
Alveolar hypoxia can cause hypoxemia, and alveolar hypocarbia can
depress respiratory drive, which may exacerbate hypoxemia
N2O
N- 79%
O2-21%O2-21%
N- 79%
N2O
O2-16%
N-70%
N2O-14%
PULMONARY
CAPILLARY
 MAC - is the alveolar concentration of
an anesthetic at 1 atm that prevents
movement in response to a surgical
stimulus in 50% of patients.
 Analogous to the ED50 expressed for
intravenous drugs.
 MAC value is a measure of inhalational
anesthetic potency.
AGENT MAC POTENCY
Methoxy-flurane 0.16% Most potent
Halothane 0.74%
Isoflurane 1.17%
Enflurane 1.7%
Sevoflurane 2.05%
Desflurane 6.0%
Nitrous oxide 104% Least potent
The lower the MAC– the more potent the agent!
Standard MAC values are roughly additive !!!
Administering 0.5 MAC of a potent
agent and 0.5 MAC of nitrous
oxide is equivalent to 1 MAC of
potent agent.
MAC effects for other response parameters are
not necessarily additive !!!
Combining 0.6 MAC of nitrous
oxide with 0.6 MAC of isoflurane
produces less hypotension than
1.2 MAC of isoflurane alone.
MAC awake: MAC allowing voluntary response to
command in 50% of patients(0.15 – 0.5 MAC)
MAC 95%: MAC that prevents movement in 95 % of
patients (1.2-1.3 MAC or +25% of MAC)
MAC intubation: MAC that allows intubation without
muscle relaxant, coughing or bucking in 50% of
patients.
MAC-BAR (1.7-2.MAC or +50% of stand. MAC), which
is the concentration required to block autonomic
reflexes to nociceptive stimuli.
MAC in Subjects Ages 30 to 60
Inhaled
Anesthetics
In O2 60%-70%
N2O
MACAWAKE MAC BAR
Desflurane 6.6% 2.83% 2.42% 1.45 MAC
Sevoflurane 1.8% 0.66% 0.61% 2.24 MAC
Isoflurane 1.17% 0.56% 0.39% 1.30 MAC
Halothane 0.75% 0.29% 0.41% 1.30 MAC
MAC decreases with
age - 6% per decade
(similar between agents)
MAC- is maximum at 6
months
 Duration of inhaled anesth. administration
 Gender
 Type of surgical stimulation
 Thyroid function
 Hypo- or hypercarbia
 Metabolic alkalosis
 Hyperkalemia
 And magnesium levels
Red-haired females have a 19% increase in MAC compared with
dark-haired females. These data suggest involvement of mutations
of the MCIR(melanocyte stimulating hormone receptor) allele.
Classification of
inhalational anaesthetics
Outdated Gases Volatile agents
 Ether
 trilene
Methoxyflurane
Cyclopropane
 chloroform
 Nitrous oxide
 Xenon
 Halothane
 Enflurane
 Isoflurane
 Sevoflurane
 Desflurane
Structural activity-relationship
2-chloro,bromo
1-trifluro ethane.
Methyl –isopropyl
ether.
2-fluro,1-trifluro
methyl ethyl ether.
2-chloro 1-trifluro
methyl-ethyl ether.
1-chloro ,fluro
2-difluro methyl-
ethyl ether.
 All agents cause CBF, causing ICP(especially
Halothane) and impair autoregulation of vascular
tone( least with sefoflurane at<1MAC)
 Volatile agents cerebral metabolic rate, N2O may
 Desflurane and isoflurane at < 1 MAC can suppress
status epilepticus while sevoflurane concentrations
associated whith epileptiform EEG.
 All agents SEP/MEP signals.(sensory-evoked potentials
and motor-evoked potentials (MEPs).
 All agents decreases CMRO2 :
Desflurane=Isoflurane=Sevoflurane>Halothane
 Cerebral Metabolic Rate and Electroencephalogram
EEG an isoelectric-no further decreases in CMR are
generate, however:
Desflurane-induced isoelectric EEG reverts to
continuous activity with time, despite an unchanging
MAC, a property unique to Desflurane
All of the potent agents depress CMR to
varying degrees !!!
 Isoflurane abolishes EEG activity at doses
used clinically, while Sevoflurane and
Desflurane at 2 MAC
 Desflurane and Isoflurane at < 1 MAC
can suppress status epilepticus while
Sevoflurane concentrations associated whith
epileptiform EEG.
All of the potent agents increase CBF in a time-
dependent as well as dose-dependent manner !!!
Desflurane=Isoflurane=Sevoflurane<Halothane
The increase in CBF with increasing dose caused by the
potent agents occurs despite decreases in CMR -
cerebral uncoupling .
↓CMR→ vasoconstrictia (physiologicly), with VA
vasodilatory effect
Because the volatile anesthetics are direct
vasodilators, all are considered to diminish
autoregulation in a dose-dependent fashion.
Sevoflurane preserves autoregulation up to approx.1MAC.
At 1.5 MAC sevoflurane preserves better than isoflurane(This
may be a result of less of a direct vasodilator effect of
sevoflurane).
0.5 MAC desflurane reduced autoregulation and
isoflurane did not. At 1.5 MAC, both anesthetics
substantially reduced autoregulation.
 Significant hypercapnia is associated with
dramatic increases in CBF whether or not
volatile anesthetics are administered.
 Hypocapnia can blunt or abolish volatile
anesthetic-induced increases in CBF
depending on when the hypocapnia is
produced.
The increase in CBF→ ↑ICP
Isoflurane, sevoflurane and desflurane >1 MAC
produce mild increases in ICP, paralleling their mild
increases in CBF.
All three potent agents may be used at appropriate
doses, especially with adjunctive and compensatory
therapies, in just about any neurosurgical procedure.
 Isoflurane does not appear to alter CSF production,
but may increase, decrease, or leave unchanged the
resistance to resorption depending on dose.
 Sevoflurane at 1 MAC depresses CSF production up
to 40%.
 Desflurane at 1 MAC leaves CSF production
unchanged or increased.
In general, anesthetic effects on ICP via changes in
CSF dynamics are clinically far less important than
anesthetic effects on CBF.
A common effect of the potent
volatile anesthetics has been a
dose-related decrease in arterial
blood pressure
Primary mechanism to decrease
blood pressure with increasing dose
is lowering regional and systemic
vascular resistance.
Sevoflurane up to about 1 MAC
results in minimal, if any, changes in
steady-state heart rate while
enflurane, isoflurane, and
desflurane increase it 5 to 10% from
baseline
Isoflurane, desflurane, and sevoflurane resulted in
a dose-dependent depression of myocardial function
with no differences between the three anesthetics.
Despite the small reduction in
baseline contractility, the
volative anesthetics did not
affect the ability of the
myocardium to respond to an
acute increase in cardiac
preload.
 Most of the volatile anesthetics have been studied
during both controlled and spontaneous ventilation.
 Spontaneous ventilation(SV) reduces the high
intrathoracic pressures from positive pressure
ventilation.
 The negative intrathoracic pressure during the
inspiratory phase of spontaneous ventilation augments
venous return and cardiac filling and improves cardiac
output and, hence, blood pressure.
 SV is associated with higher PaCO2, causing cerebral
and systemic vascular relaxation. This contributes to an
improved cardiac output via afterload reduction.
 It has been suggested that spontaneous ventilation
might improve the safety of inhaled anesthetic
administration because:
Concentration of a VA that produces
cardiovascular collapse > the conc. that
results in apnea.
 Oxygen consumption is decreased approximately
10 to 15% during general anesthesia.
 The distribution of cardiac output also is altered by
anesthesia. Blood flow to liver, kidneys, and gut is
decreased, particularly at deep levels of anesthesia.
- In contrast, blood flow to the brain, muscle, and skin
is increased or not changed.
 Sinoatrial node discharge rate is slowed by the
volatile anesthetics. Conduction in the His-
Purkinje system also is prolonged by the volatile
anesthetics.
 Isoflurane (and most other potent volatile anesthetics)
increases coronary blood flow many times beyond
that of the myocardial oxygen demand, thereby
creating potential for “steal.”
 Steal is the diversion of blood from a myocardial bed
with limited or inadequate perfusion to a bed with
more adequate perfusion.
 Neither isoflurane, sevoflurane, or desflurane at
concentrations up to 1.5 MAC cause steal effect.
 There are only minor effects on decreasing
minute ventilation.
 The ventilatory effects are dose-dependent.
 Their net effect of a gradual decrease in
minute ventilation has been associated with
increasing resting Paco2.
All volatile anesthetics decrease tidal volume
↓(TV) and increase respiratory rate ↑(RR)
Isoflurane does not
increase respiratory rate
above 1 MAC.
N2O increases respiratory
rate as much or more than
the inhaled anesthetics.
Desflurane results in the
greatest increase in
Paco2 .
 In awake humans, changes in arterial CO2 such that
minute ventilation increases 3 L/min per a 10-mm Hg
increase in Paco2.
All inhaled anesthetics
produce a dose-dependent
depression of the ventilatory
response to hypercarbia!
The threshold at which
breathing stops, called the
apneic threshold.
It is generally 4 to 5 mm Hg below
the prevailing resting Paco2
Ing.Anesth., including nitrous oxide, produce a dose-
dependent attenuation of the ventilatory response to
hypoxia.
Has important clinical implications
The short-acting sevoflurane and
desflurane may prove
advantageous - more rapid
washout and their minimal effect
on hypoxic sensitivity at
subanesthetic concentrations.
Bronchoconstriction under anesthesia occur:
 direct stimulation of the laryngeal and tracheal areas
 administration of adjuvant drugs that cause histamine
release
 noxious stimuli activating vagal afferent nerves
The reflex response to these stimuli may be enhanced :
- in lightly anesthetized patients
- in patients with known reactive airway disease
including those requiring bronchodilator therapy
- chronic smoking histories.
 Bronchoconstriction - via M2 and M3 muscarinic
receptors, which initiate increases in intracellular
cyclic guanosine monophosphate(cGMP).
 Bronchiolar muscle relaxation – adrenergic β2-
receptors → an increase in intracellular cyclic
adenosine monophosphate(cAMP).
The volatile anesthetics relax airway smooth muscle
primarily by directly depressing smooth muscle
contractility and indirectly inhibiting the reflex
neural pathway!
Volatile anesthetics have been used effectively to treat
status asthmaticus when other conventional treatments
have failed!
Sevoflurane may be a better choice.
Smokers have impaired mucociliary function compared
with nonsmokers.
and the combination of a volatile anesthetic in a smoker
who is mechanically ventilated sets up a scenario for
inadequate clearing of secretions, mucus plugging,
atelectasis, and hypoxemia.
Volatile anesthetics and nitrous oxide reduce
ciliary movement and alter the characteristics
of mucus.
Inadequate hepatocyte oxygenation (oxygen supply
relative to oxygen demand) is the principal mechanism
responsible for hepatic dysfunction following anesthesia
and surgery.
The liver has two blood supplies:
1 Hepatic artery(well-oxygenated).
2 Portal vein( poorly oxygenated).
Postoperative liver dysfunction has been associated with
most volatile anesthetics, with halothane receiving the
most attention.
HBF-Desflurane=Isoflurane=Sevoflurane<Halothane
The ether-based anesthetics
(isoflurane, sevoflurane, desflurane)
maintain or increase hepatic artery
blood flow while decreasing (or not
changing) portal vein blood flow.
Halothane decreases in both
portal vein and hepatic artery
blood flow, thereby significantly
compromising total hepatic artery
blood flow.
 Altered liver function tests have been used as an
index of hepatic injury during anesthesia.
 ALT, AST, GST
 Increases in the ALT or AST are not uniquely
specific to the liver.
 The centrilobular area of the liver is most
susceptible to hypoxia.
 A more sensitive measure GST(α-glutathione S-
transferase), since it is distributed primarily in the
centrilobular hepatocytes.
The inhaled anesthetics have two important actions on
neuromuscular function:
1. Directly relax skeletal muscle(nitrous oxide does not).
2. Potentiate the action of neuromuscular blocking drugs.
All of the potent volatile anesthetics
serve as triggers for malignant
hyperthermia (MH)!!!
While N2O is considered safe in MH-susceptible
patients!!!
 Uterine smooth muscle tone is diminished by volatile
anesthetics.
 There is a dose-dependent decrease in spontaneous
myometrial contractility.
 Uterine relaxation/atony can become problematic at
concentrations of volatile anesthesia >1 MAC, and
might delay the onset time of newborn respiration.
 Consequently, a common technique used to provide
GA for urgent CS is to administer low concentrations
of the VA, such as 0.5 to 0.75 MAC, combined with N20
Volatile anesthetics produce similar dose-related
decreases in renal blood flow, glomerular
filtration rate, and urine output.
These changes most likely reflect the effects of
volatile anesthetics on systemic blood pressure and
cardiac output.
Preoperative hydration attenuates or abolishes many
of the changes in renal function associated with
volatile anesthetics.
Physical properties:
 It is a laughing gas,colorless and odorless
 It is only inorganic anesthetic gas in clinical use.
 Non Explosive and Non Inflammable
 Gas at room temperature and can be kept as a liquid
under pressure.
 It is relatively inexpensive.
 low potency (MAC = 104%) and is relatively insoluble in
blood
 Nitrous oxide does not produce significant skeletal
muscle relaxation, but it does have analgesic effects.
 Elimination: almost 100% exhalation.
 It causes post operative Nausea and Vomiting
 Oxidizes Co atom in vitamin B12, inactivates
methinoine synthetase
 Affects myelin formation →peripheral neuropathies,
neurotoxicity.
 Homocysteine accumulation
 Inhibits thymidylate syntetase(DNA
syntesis)→teratogenicity.
 Bone marrow depression-megaloblastic anemia
 Air embolism
 Pneumothorax
 Acute Intestinal Obstruction
 Tension Pneumocephalus
 Tympanic membrane grafting
75% nitrous oxide can expand a pneumo-
thorax to double or triple its size in 10 and
30 minutes!!!
 Physical Properties:
 It is halogenated alkene.
 Sweet, non-pungent.
 Non Inflammable and Non explosive.
 Least expensive .
 CV: myocardial depression
- ↓BP and CO by up to 50%
- causes slowing of SA node conduction resulting in
bradycardia
 Resp: ↑RR, ↓↓TV, ↓MV, ↓↓hypercapnic drive, potent
bronchodilator.
 CEREBRAL:
It increases cerebral blood flow.
 NEUROMUSCULAR:
Relaxes skelatal muscle and potentiates Non
depolarizing neuro-muscular blocking agents.
 RENAL:
Reduces renal blood flow, glomerular filtration rate
and urinary output.
 Hepatic
↓hepatic blood flow: impaired hepatic drug clearance.
-Liver oxidation→trifluoroacetic acid(TFA)
- 20% metabolised
- 1in 5 adults hepatotoxicity(lethargy, nausea,fever)
likely related to changes in HBF.
-”Halothane hepatitis”(rare): massive hepatic necrosis.
likely immune mechanism(eosinophilia, rash, fever)
 Contraindications:
 Unexplained liver dysfunction.
 Intra-cranial mass lesions.
 Hypovolemic patient with severe cardiac diseases
 Isoflurane is a halogenated methyl ethyl ether
 Clear, nonflammable liquid at room temperature.
 Has a high degree of pungency.
 It has become the “gold standard” anesthetic since its
introduction in the 1970s
 Contraindications:
 No such contraindication.
 Patient with severe hypovolemia may not tolorate its
vasodilating effects.
It is the most potent of the volatile
anesthetics in clinical use.
 Sevoflurane is a sweet-smelling, completely fluorinated
methyl isopropyl ether
 Non-pungent, low solubility- exellent for inhalation
induction
 +muscle relaxation(enough for peds intubation)
potentiates NMBA.
 Elimination:
-5%-liver metabolism
 BaOH, soda lime- Compound A
-nephrotoxic in rats
-but has not been associated with renal injury in
human volunteers or patients, with or without renal
impairment, even when fresh gas flows are 1 L/min or less.
 Very similar to Isoflurane in structure but much less
soluble, less potent.
 Very high vapor pressure - requires special vaporizer.
- can boil at normal OR temperature.
- special vaporizer heats it to a gas and then blends it
with the FGF.
Desflurane is the most pungent
of the VA !!!
and if administered via the face mask results in:
coughing,salivation,breath holding,and laryngospasm.
Desflurane has the lowest blood:gas
solubility of the potent VA
 Is an inert gas, difficult to obtain, and hence extremely
expensive.
 It has many characteristics approaching those of an
“ideal” inhaled anesthetic.
 Nonexplosive, nonpungent, and odorless, and thus can
be inhaled with ease.
 Its blood:gas partition coefficient is 0.14, and unlike the
other potent VA , xenon provides some degree of
analgesia.
 Does not produce significant myocardial depression.
 Because of its scarcity and high cost, new anesthetic
systems need to be developed to provide for recycling
of xenon.
Differential Physiologic Effects of Inhaled Anesthetics
N2O Halothane Isoflurane Sevoflurane Desflurane
HR or or
SVR
CO or or
Contractility
HBF
HBF- hepatic blood flow, HR- heart rate, CO-cardiac output, SVR-systemic vascular resist.,
and -slight or mild change, - significant decrease, - no change.

More Related Content

What's hot

Low flow Anaesthesia & Gas Monitoring
Low flow Anaesthesia & Gas MonitoringLow flow Anaesthesia & Gas Monitoring
Low flow Anaesthesia & Gas Monitoring
Kalpesh Shah
 
Mapleson breathing systems
Mapleson breathing systemsMapleson breathing systems
Mapleson breathing systems
drdeepak016
 
Low flow anaesthesia
Low flow anaesthesiaLow flow anaesthesia
Low flow anaesthesia
ZIKRULLAH MALLICK
 
Intro to Hypoxic pulmonary vasoconstriction
Intro to Hypoxic pulmonary vasoconstriction Intro to Hypoxic pulmonary vasoconstriction
Intro to Hypoxic pulmonary vasoconstriction
Arun Shetty
 
Circle system low flow anesthesia
Circle system low flow anesthesiaCircle system low flow anesthesia
Circle system low flow anesthesiaDrgeeta Choudhary
 
Breathing circuit
Breathing circuitBreathing circuit
Breathing circuit
Khyber Teaching hospital
 
Vaporizers in Anesthesia
Vaporizers in AnesthesiaVaporizers in Anesthesia
Vaporizers in Anesthesia
Mohin George
 
Thrive
ThriveThrive
Thrive
Shreyas Kate
 
Baska mask
Baska mask Baska mask
Baska mask
rashidmkhan
 
AWAKE FIBEROPTIC INTUBATION & TIVA- simplified
AWAKE FIBEROPTIC INTUBATION & TIVA- simplifiedAWAKE FIBEROPTIC INTUBATION & TIVA- simplified
AWAKE FIBEROPTIC INTUBATION & TIVA- simplified
National hospital, kandy
 
Vaporizers
Vaporizers Vaporizers
Vaporizers
narasimha reddy
 
Breathing systems
Breathing systemsBreathing systems
Breathing systems
Brijesh Savidhan
 
Inhalational anaesthetics
Inhalational anaestheticsInhalational anaesthetics
Inhalational anaesthetics
kamalrajkumar1
 
Breathing circuit's
Breathing circuit'sBreathing circuit's
Breathing circuit'sImran Sheikh
 
Physics In Anaesthesia
Physics In AnaesthesiaPhysics In Anaesthesia
Physics In Anaesthesia
NARENDRA PATIL
 
O2 cascade flux n odc
O2 cascade flux n odcO2 cascade flux n odc
O2 cascade flux n odc
Rony Mathew
 
Anaesthesia breathing systems
Anaesthesia breathing systemsAnaesthesia breathing systems
Anaesthesia breathing systems
D Nkar
 
Minimum alveolar concentration (mac)
Minimum alveolar concentration (mac)Minimum alveolar concentration (mac)
Minimum alveolar concentration (mac)
Torrentz Tiku
 
Lfa
LfaLfa

What's hot (20)

Low flow Anaesthesia & Gas Monitoring
Low flow Anaesthesia & Gas MonitoringLow flow Anaesthesia & Gas Monitoring
Low flow Anaesthesia & Gas Monitoring
 
Mapleson breathing systems
Mapleson breathing systemsMapleson breathing systems
Mapleson breathing systems
 
Low flow anaesthesia
Low flow anaesthesiaLow flow anaesthesia
Low flow anaesthesia
 
Intro to Hypoxic pulmonary vasoconstriction
Intro to Hypoxic pulmonary vasoconstriction Intro to Hypoxic pulmonary vasoconstriction
Intro to Hypoxic pulmonary vasoconstriction
 
Circle system low flow anesthesia
Circle system low flow anesthesiaCircle system low flow anesthesia
Circle system low flow anesthesia
 
Breathing circuit
Breathing circuitBreathing circuit
Breathing circuit
 
Vaporizers in Anesthesia
Vaporizers in AnesthesiaVaporizers in Anesthesia
Vaporizers in Anesthesia
 
Thrive
ThriveThrive
Thrive
 
Baska mask
Baska mask Baska mask
Baska mask
 
Breathing systems (2)
Breathing systems (2)Breathing systems (2)
Breathing systems (2)
 
AWAKE FIBEROPTIC INTUBATION & TIVA- simplified
AWAKE FIBEROPTIC INTUBATION & TIVA- simplifiedAWAKE FIBEROPTIC INTUBATION & TIVA- simplified
AWAKE FIBEROPTIC INTUBATION & TIVA- simplified
 
Vaporizers
Vaporizers Vaporizers
Vaporizers
 
Breathing systems
Breathing systemsBreathing systems
Breathing systems
 
Inhalational anaesthetics
Inhalational anaestheticsInhalational anaesthetics
Inhalational anaesthetics
 
Breathing circuit's
Breathing circuit'sBreathing circuit's
Breathing circuit's
 
Physics In Anaesthesia
Physics In AnaesthesiaPhysics In Anaesthesia
Physics In Anaesthesia
 
O2 cascade flux n odc
O2 cascade flux n odcO2 cascade flux n odc
O2 cascade flux n odc
 
Anaesthesia breathing systems
Anaesthesia breathing systemsAnaesthesia breathing systems
Anaesthesia breathing systems
 
Minimum alveolar concentration (mac)
Minimum alveolar concentration (mac)Minimum alveolar concentration (mac)
Minimum alveolar concentration (mac)
 
Lfa
LfaLfa
Lfa
 

Viewers also liked

Inhalational anaesthetics pharmacokinetics & pharmacodynamics, uptake & distr...
Inhalational anaesthetics pharmacokinetics & pharmacodynamics, uptake & distr...Inhalational anaesthetics pharmacokinetics & pharmacodynamics, uptake & distr...
Inhalational anaesthetics pharmacokinetics & pharmacodynamics, uptake & distr...Swadheen Rout
 
Sevoflurane in neuroanaesthesia
Sevoflurane in neuroanaesthesiaSevoflurane in neuroanaesthesia
Sevoflurane in neuroanaesthesianarasimha reddy
 
Desflurane
DesfluraneDesflurane
Desflurane
Sun City
 
Inhalant anaesthetics
Inhalant anaestheticsInhalant anaesthetics
Inhalant anaesthetics
Dr Alok Bharti
 
Pharmacokinetics of Inhalational Anaesthetics
Pharmacokinetics of Inhalational AnaestheticsPharmacokinetics of Inhalational Anaesthetics
Pharmacokinetics of Inhalational Anaesthetics
Dr.S.N.Bhagirath ..
 
Intravenous induction agents
Intravenous induction agentsIntravenous induction agents
Intravenous induction agents
anaesthesiology-mgmcri
 
Inhalational anes
Inhalational anesInhalational anes
Inhalational anesgaganbrar18
 
Inhalational anaesthetic agents
Inhalational anaesthetic agentsInhalational anaesthetic agents
Inhalational anaesthetic agentsgaganbrar18
 
αυτοκίνητο
αυτοκίνητοαυτοκίνητο
αυτοκίνητοpapathe
 
Comparative Evaluation of Recovery Characteristic and Consumption of Desflura...
Comparative Evaluation of Recovery Characteristic and Consumption of Desflura...Comparative Evaluation of Recovery Characteristic and Consumption of Desflura...
Comparative Evaluation of Recovery Characteristic and Consumption of Desflura...
Apollo Hospitals
 
Solution chemistry enthalpy
Solution chemistry   enthalpySolution chemistry   enthalpy
Solution chemistry enthalpy
ewalenta
 
Pharma ga
Pharma gaPharma ga
Pharma ga
Rakesh Kumar
 
Aditi M. Panditrao's Inhalational anaes agents
Aditi M. Panditrao's Inhalational anaes agentsAditi M. Panditrao's Inhalational anaes agents
Aditi M. Panditrao's Inhalational anaes agents
Prof. Mridul Panditrao
 
Pharmacokinetics of inhalational agents relavant to anaestheist
Pharmacokinetics of inhalational agents relavant to anaestheistPharmacokinetics of inhalational agents relavant to anaestheist
Pharmacokinetics of inhalational agents relavant to anaestheistnarasimha reddy
 
iOS App Map
iOS App MapiOS App Map
iOS App Map
Chetan Sharma
 
Ketamine as a neuroapoptotic agent
Ketamine as a neuroapoptotic agentKetamine as a neuroapoptotic agent
Ketamine as a neuroapoptotic agent
aparna jayara
 

Viewers also liked (20)

Inhalational anaesthetics pharmacokinetics & pharmacodynamics, uptake & distr...
Inhalational anaesthetics pharmacokinetics & pharmacodynamics, uptake & distr...Inhalational anaesthetics pharmacokinetics & pharmacodynamics, uptake & distr...
Inhalational anaesthetics pharmacokinetics & pharmacodynamics, uptake & distr...
 
Sevoflurane in neuroanaesthesia
Sevoflurane in neuroanaesthesiaSevoflurane in neuroanaesthesia
Sevoflurane in neuroanaesthesia
 
Desflurane
DesfluraneDesflurane
Desflurane
 
Inhalant anaesthetics
Inhalant anaestheticsInhalant anaesthetics
Inhalant anaesthetics
 
Inhalational Agents
Inhalational AgentsInhalational Agents
Inhalational Agents
 
Pharmacokinetics of Inhalational Anaesthetics
Pharmacokinetics of Inhalational AnaestheticsPharmacokinetics of Inhalational Anaesthetics
Pharmacokinetics of Inhalational Anaesthetics
 
Intravenous induction agents
Intravenous induction agentsIntravenous induction agents
Intravenous induction agents
 
Inhalational anes
Inhalational anesInhalational anes
Inhalational anes
 
Inhalational anaesthetic agents
Inhalational anaesthetic agentsInhalational anaesthetic agents
Inhalational anaesthetic agents
 
ITE target review volatile anesthetics
ITE target review volatile anestheticsITE target review volatile anesthetics
ITE target review volatile anesthetics
 
αυτοκίνητο
αυτοκίνητοαυτοκίνητο
αυτοκίνητο
 
Comparative Evaluation of Recovery Characteristic and Consumption of Desflura...
Comparative Evaluation of Recovery Characteristic and Consumption of Desflura...Comparative Evaluation of Recovery Characteristic and Consumption of Desflura...
Comparative Evaluation of Recovery Characteristic and Consumption of Desflura...
 
Solution chemistry enthalpy
Solution chemistry   enthalpySolution chemistry   enthalpy
Solution chemistry enthalpy
 
Pharma ga
Pharma gaPharma ga
Pharma ga
 
Aditi M. Panditrao's Inhalational anaes agents
Aditi M. Panditrao's Inhalational anaes agentsAditi M. Panditrao's Inhalational anaes agents
Aditi M. Panditrao's Inhalational anaes agents
 
Pharmacokinetics of inhalational agents relavant to anaestheist
Pharmacokinetics of inhalational agents relavant to anaestheistPharmacokinetics of inhalational agents relavant to anaestheist
Pharmacokinetics of inhalational agents relavant to anaestheist
 
iOS App Map
iOS App MapiOS App Map
iOS App Map
 
Aneogy
AneogyAneogy
Aneogy
 
Ketamine as a neuroapoptotic agent
Ketamine as a neuroapoptotic agentKetamine as a neuroapoptotic agent
Ketamine as a neuroapoptotic agent
 
Thiopentone upendra
Thiopentone upendraThiopentone upendra
Thiopentone upendra
 

Similar to Ingalation anesthetics

uptakeandsistributionofinhaledanesthetic-170601153634.pdf
uptakeandsistributionofinhaledanesthetic-170601153634.pdfuptakeandsistributionofinhaledanesthetic-170601153634.pdf
uptakeandsistributionofinhaledanesthetic-170601153634.pdf
UmaKumar14
 
General principles of pharmacology of inhalational agents(Pharmacokinetics)
General principles of pharmacology of inhalational agents(Pharmacokinetics)General principles of pharmacology of inhalational agents(Pharmacokinetics)
General principles of pharmacology of inhalational agents(Pharmacokinetics)
DR PANKAJ KUMAR
 
inhalational-170618171316 (1).pdf
inhalational-170618171316 (1).pdfinhalational-170618171316 (1).pdf
inhalational-170618171316 (1).pdf
Keerthy Unnikrishnan
 
Inhalational Anesthetic Agents
Inhalational Anesthetic AgentsInhalational Anesthetic Agents
Inhalational Anesthetic Agents
Milan Kharel
 
Pharmacokinetics of inhalational agents relavant to anaestheist
Pharmacokinetics of inhalational agents relavant to anaestheistPharmacokinetics of inhalational agents relavant to anaestheist
Pharmacokinetics of inhalational agents relavant to anaestheistnarasimha reddy
 
inhalation part 2.pptx
inhalation part 2.pptxinhalation part 2.pptx
inhalation part 2.pptx
ssuser579a28
 
inhalational Anesthetic agents drugs.pptx
inhalational Anesthetic agents drugs.pptxinhalational Anesthetic agents drugs.pptx
inhalational Anesthetic agents drugs.pptx
PARTHIKKALARIYA
 
seminar on hfv - high frequency ventilation
seminar on hfv - high frequency ventilationseminar on hfv - high frequency ventilation
seminar on hfv - high frequency ventilation
Dr. Habibur Rahim
 
Respiration powerpoint
Respiration powerpointRespiration powerpoint
Respiration powerpointMissReith
 
Respiratory Physiology & Respiratory Function During Anesthesia
Respiratory Physiology & Respiratory Function During AnesthesiaRespiratory Physiology & Respiratory Function During Anesthesia
Respiratory Physiology & Respiratory Function During AnesthesiaDang Thanh Tuan
 
Inhalational agent.pptx
Inhalational agent.pptxInhalational agent.pptx
Inhalational agent.pptx
Tess Jose
 
Neonatal assisted ventilation
Neonatal assisted ventilation   Neonatal assisted ventilation
Neonatal assisted ventilation Abdul Fatah Abro
 
1578623596886_Respiratory Physio.ppt ccm
1578623596886_Respiratory Physio.ppt ccm1578623596886_Respiratory Physio.ppt ccm
1578623596886_Respiratory Physio.ppt ccm
NishanthTR
 
Pathophysiology of hypoxic respiratory failure
Pathophysiology of hypoxic respiratory failurePathophysiology of hypoxic respiratory failure
Pathophysiology of hypoxic respiratory failureAndrew Ferguson
 
Ventilator-waveform-analysis_nagarjuna_2012.pdf
Ventilator-waveform-analysis_nagarjuna_2012.pdfVentilator-waveform-analysis_nagarjuna_2012.pdf
Ventilator-waveform-analysis_nagarjuna_2012.pdf
JoyMitra16
 

Similar to Ingalation anesthetics (20)

uptakeandsistributionofinhaledanesthetic-170601153634.pdf
uptakeandsistributionofinhaledanesthetic-170601153634.pdfuptakeandsistributionofinhaledanesthetic-170601153634.pdf
uptakeandsistributionofinhaledanesthetic-170601153634.pdf
 
General principles of pharmacology of inhalational agents(Pharmacokinetics)
General principles of pharmacology of inhalational agents(Pharmacokinetics)General principles of pharmacology of inhalational agents(Pharmacokinetics)
General principles of pharmacology of inhalational agents(Pharmacokinetics)
 
inhalational-170618171316 (1).pdf
inhalational-170618171316 (1).pdfinhalational-170618171316 (1).pdf
inhalational-170618171316 (1).pdf
 
Inhalational Anesthetic Agents
Inhalational Anesthetic AgentsInhalational Anesthetic Agents
Inhalational Anesthetic Agents
 
Pharmacokinetics of inhalational agents relavant to anaestheist
Pharmacokinetics of inhalational agents relavant to anaestheistPharmacokinetics of inhalational agents relavant to anaestheist
Pharmacokinetics of inhalational agents relavant to anaestheist
 
inhalation part 2.pptx
inhalation part 2.pptxinhalation part 2.pptx
inhalation part 2.pptx
 
inhalational Anesthetic agents drugs.pptx
inhalational Anesthetic agents drugs.pptxinhalational Anesthetic agents drugs.pptx
inhalational Anesthetic agents drugs.pptx
 
seminar on hfv - high frequency ventilation
seminar on hfv - high frequency ventilationseminar on hfv - high frequency ventilation
seminar on hfv - high frequency ventilation
 
Respiration powerpoint
Respiration powerpointRespiration powerpoint
Respiration powerpoint
 
Ards
ArdsArds
Ards
 
Respiratory Physiology & Respiratory Function During Anesthesia
Respiratory Physiology & Respiratory Function During AnesthesiaRespiratory Physiology & Respiratory Function During Anesthesia
Respiratory Physiology & Respiratory Function During Anesthesia
 
Inhalational agent.pptx
Inhalational agent.pptxInhalational agent.pptx
Inhalational agent.pptx
 
Neonatal assisted ventilation
Neonatal assisted ventilation   Neonatal assisted ventilation
Neonatal assisted ventilation
 
Ventilators
Ventilators Ventilators
Ventilators
 
1578623596886_Respiratory Physio.ppt ccm
1578623596886_Respiratory Physio.ppt ccm1578623596886_Respiratory Physio.ppt ccm
1578623596886_Respiratory Physio.ppt ccm
 
Pathophysiology of hypoxic respiratory failure
Pathophysiology of hypoxic respiratory failurePathophysiology of hypoxic respiratory failure
Pathophysiology of hypoxic respiratory failure
 
Respiratory Physiology
Respiratory PhysiologyRespiratory Physiology
Respiratory Physiology
 
Respiratory Physiology
Respiratory PhysiologyRespiratory Physiology
Respiratory Physiology
 
Respiratory Physiology
Respiratory PhysiologyRespiratory Physiology
Respiratory Physiology
 
Ventilator-waveform-analysis_nagarjuna_2012.pdf
Ventilator-waveform-analysis_nagarjuna_2012.pdfVentilator-waveform-analysis_nagarjuna_2012.pdf
Ventilator-waveform-analysis_nagarjuna_2012.pdf
 

Recently uploaded

Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Dr KHALID B.M
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
Little Cross Family Clinic
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
i3 Health
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
Krishan Murari
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
Anurag Sharma
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Dr Jeenal Mistry
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
VarunMahajani
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
vimalpl1234
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
DrSathishMS1
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 

Recently uploaded (20)

Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 UpakalpaniyaadhyayaCharaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
Charaka Samhita Sutra sthana Chapter 15 Upakalpaniyaadhyaya
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Are There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdfAre There Any Natural Remedies To Treat Syphilis.pdf
Are There Any Natural Remedies To Treat Syphilis.pdf
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
BRACHYTHERAPY OVERVIEW AND APPLICATORS
BRACHYTHERAPY OVERVIEW  AND  APPLICATORSBRACHYTHERAPY OVERVIEW  AND  APPLICATORS
BRACHYTHERAPY OVERVIEW AND APPLICATORS
 
micro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdfmicro teaching on communication m.sc nursing.pdf
micro teaching on communication m.sc nursing.pdf
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdfAlcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
Alcohol_Dr. Jeenal Mistry MD Pharmacology.pdf
 
Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...
 
Knee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdfKnee anatomy and clinical tests 2024.pdf
Knee anatomy and clinical tests 2024.pdf
 
24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all24 Upakrama.pptx class ppt useful in all
24 Upakrama.pptx class ppt useful in all
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 

Ingalation anesthetics

  • 1.
  • 2. Joseph Priestly – discovers N2O in 1773 Crawford W. Long – 1842. Country Dr. in Georgia first used ether for neck surgery. Did not publicize. Tried to claim credit after Morton’s demonstration but… Important lesson learned – if you don’t publish it, it didn’t happen. Sir Humphrey Davy – experimented with N2O, reported loss of pain, euphoria Horace Wells 1844. Demonstrated N2O for tooth extraction – deemed a failure because patient “reacted”. History of Anesthesia
  • 3. WORLD ANAESTHESIA DAY 16TH OCT 1846 W.T.G.MORTON John Collin Warren Gilbert Abortt
  • 4. How do Inhalational Anesthetics Work? Surprisingly, the mechanism of action is still largely unknown. "Anesthetics have been used for 160 years, and how they work is one of the great mysteries of neuroscience," James Sonner, M.D. (UCSF) Lipid Theory Membrane Stabilization Theory Promiscuous Receptor Agonist Theory: Anesthetics may act at GABA receptors, NMDA receptors, other receptors Modifying functions of ION CHANNELS (opening of inhibitory ion channels (Cl- or K+) and closing of excitatory ion channels (Na+)
  • 5.  Speed(extremely rapid action and fast changes in level of anesthesia)  Faster turnover/recovery times  Route of administration- lungs (get 100% of cardiac output)  Margin of safety
  • 6. The main target of inhalation anesthetics is the brain.
  • 7. Goal To develop and maintain a satisfactory partial pressure or tension of anesthetic at the site of anesthetic action in brain. Alveolar concentration of anesthetic gas is indirectly reflects brain concentration. PA PB
  • 8.  Vaporizer  Breathing Circuit  Alveoli (lungs)  Arterial Blood  Tissues (VRG [brain], MUS,FAT)  Venous blood (coming back to lungs)  Alveoli (lungs, again)  Breathing Circuit (to be rebreathed)
  • 9. Time constant Uptake and distribution of anesthetic gases FI FA FD MAC Brain Partial pressure drives depth of anesthesia Equilibrates Ventilation λB/G CO PA - PV λT/B Tissue blood flow [Parterial - PTissue] 1 2 FA/FI Concentration and second gas effects Time constant VRG
  • 10.  The absorption phase is usually called - uptake  The metabolic phase is usually called - biotransformation  The excretion phase is usually called – elimination.  lowering of drug concentration in one compartment by delivery into another compartment is called redistribution
  • 11.  Partial Pressure -the pressure a gas exerts- proportional its fractional mass  Additive Patm = PO2 + PN2 =160mmHg + 600mmHg = 760mmHg  Ptotal= Pgas1+ Pgas2+ ….+Pgas N (Dalton’s law) Same pressure each gas would have if IT ALONE occupied the same volume
  • 12.  Pressure- gas phase  Concentration – amount of gas dissolved in a solution.  Solubility = volume of gas volume of liquid (at standard temperature) What is “ PARTIAL PRESSURE OF GAS” in solution? Reflects a “force” of gas to escape out of solution ( think of CO2 in a bottle of soda)
  • 13. Gasses equilibrate based on partial pressures, not on concentrations By convention, we use fractional concentration(F) instead of partial pressure(P) Ex: We could say FO2= 21% instead of PO2= 160 mmHg Thus, F is proportional to P Physiologically, our body needs the partial pressure, not the fractional concentration!!!
  • 14. Henry”s law: Cg = k Pg Cg - is concentration of gas in solution k - is a solubility constant Pg - is the partial pressure of the gas
  • 15.  Physiologically, Anesthetic gases work based on partial pressure in the brain, not fractional concentration Anesthetic gases work based on partial pressure in the brain, not fractional concentration ! The vaporizers are calibrated to deliver a set partial pressure, NOT a set fractional concentration! SEVO vaporizer only delivers 1% sevoflurane when P atm= 760mmHg. But it will always deliver(appr) the correct partial pressure of sevoflurane at any altitude. True for ALL vaporizers EXCEPT DESFLURANE
  • 16. Getting agent from the anesthesia machine into the brain so the patient goes to sleep!!!  Goal: achieve “steady state” of anesthetic partial pressures throughout the system  Vaporizer adds agent to the fresh gas flow at a fixed concentration  Fresh gas mixes with circuit gas (bag, tubing canister, piping), dilutes concentration of agent  Compartments equilibrate and concentration of agent in the circuit rises
  • 17.  Fractional concentration of agent leaving the circuit is Fi (fraction inspired)  Fractional concentration of agent in the lungs is FA (fraction alveolar)  Initially, FA/Fi = 0 because Fa is a 0 No agent in the lungs yet  These compartments will also equilibrate over time You will be at EQ when FA=Fi, or FA/Fi=1 Fast induction is defined as FA/Fi → 1 quickly
  • 19. FFGO -is the fraction of inspired anesthetic in the gas leaving the fresh gas outlet. T - is time. τ - is a time constant. The time constant is simply the volume or “capacity” of the circuit (VC) divided by the fresh gas flow (FGF) or τ = VC/FGF. Concentration in the circuit (FI) will rise according to first-order kinetics:
  • 20. Concentration of (FA) will rise analogous to Fi FA -is the alveolar concentration T - is time. τ -is a time constant. The time constant for raise of FA concentration and equals FRC/VA FRC-functional residual capacity VA- minute ventilation
  • 21.  The time required for flow through a container to equal the capacity of the container. TC is volume (capacity)/flow.  The time constant for the lungs is FRC/Valveolar.  The time constant for the anesthesia circuit is circuit capacity/FGF.
  • 22.  If 10 liter box is initially filled with oxygen and 5 l/min of nitrogen flow into box then,  TC is volume (capacity)/flow.  TC = 10 / 5 = 2 minutes ( 1 Time Constant)  So, the nitrogen concentration at end of 2 minutes is 63%. O2 10 Lt 5 Lt/min 2 Mts 4 Mts 6 Mts 8 Mts 63% 86% 95% 98% N2 Time Constant at Lungs
  • 23. Time Constants and Brain Equilibration Time constant Brain Equilibration time Isoflurane 3-4 mins 10-15 mins Sevoflurane 2 mins 6 mins Desflurane 2 mins 6 mins Nitrous Oxide 2 mins 6 mins equilibration with any tissue takes 3 time constants
  • 24. a) The inspired concentration (FI) Inspired concentration - FA/FI b) The alveolar ventilation (Valveolar) - Minute alveolar ventilation - FA/FI - Larger the FRC - slows raise of alveolar concentration c) The time constant d) Anesthetic uptake by the blood e) The concentration and second gas effects
  • 25. 1) Fresh Gas Flow rate: ↑ FGF → ↑ speed of induction & recovery. 2) Volume of breathing circuit (apparatus dead space): incr. ↑volume → slower induction (dilution of anesthetic gases.) 3) Absorption by the breathing circuit: rubber tubing absorbs ˃ plastic & silicon.
  • 26. Increase in Minute alveolar ventilation Increases FA/FI The change is greatest for more soluble anesthetics methoxyflurane - increases by 75% isoflurane - by 18% desflurane - by only 6%. negative feedback that results from respiratory depression high ventilation → rapid induction → hypoventilation
  • 27. Increase FA/FI Decrease FA/FI Comment Low blood solubility High blood solubility As the blood solubility decreases, the rate of rise in FA/FI increases. Low cardiac output High cardiac output The lower the cardiac output, the faster the rate of rise in FA/FI High minute ventilation Low minute ventilation The higher the minute ventilation, the faster the rate of rise in FA/FI Factors that Increase or Decrease the Rate of Rise of F /F Uptake from the lung = Blood solubility x Cardiac Output x [PA-PV] Bar. pressure
  • 28. 50%O2 50%N2O 2Lt 2Lt 4Lt 33%N2O 66%O2 3Lt 2Lt 1Lt Uptake of half of the N2O 38%N2O 62%O2 1Lt of N2O 1 Lt 50%O2 + 50%N2O Ventilation Effect Inspired Gas 1.5Lt 4Lt 2.5Lt The higher the inspired concentration, the more rapid the rise in alveol. concentration . The concentration effect is only significant for gases present in high concentrations (e.g. nitrous).
  • 29. . Two components: 1.the concentrating effect 2.an augmented gas inflow effect
  • 30.
  • 31. Administration of 70% nitrous oxide produces a more rapid rise in the FA/FI ratio of nitrous oxide than administration of 10% nitrous oxide The FA/FI ratio for 0.5% halothane rises more rapidly when given with 70% nitrous oxide than when given with 10% nitrous oxide. Concentration effect Second gas effect
  • 32. Factors raising the alveolar concentration (FA/FI ) a) The inspired concentration (FI) b) The alveolar ventilation (Valveolar) c) The time constant d) Anesthetic uptake by the blood e) The concentration and second gas effects
  • 33. Factors determining uptake by blood A. Solubility in blood B. Cardiac Output C. The mixed venous anesthetic concentration d. Tissue uptake of anesthetic
  • 34. Uptake from the lung = Blood solubility x Cardiac Output x [PA-PV] Barometric pressure U Lung = λB/G x Q x ((PA-Pvenous) Barometric pressure Fick equation λB/G - blood:gas partition coefficient Q - cardiac output PA - alveolar partial pressure of anesthetic Pv - mixed venous partial pressure of anesthetic PB is barometric pressure.
  • 35.  Solubility is defined in terms of the partition coefficient  Partition coefficient is the ratio of the amount of substance present in one phase compared with another, the two phases being of equal volume and in equilibrium [λB/G = CB ] CG
  • 36. Gas Blood Partition Coefficient = Ratio of Concentration Concentrations Equilibirates Partial pressure Equalize CG =CB PG = PB Halothane λB/G = CB = 2.5 = 2.5 CG 1 Equal volume Partial pressures are equal but concentrations are not !!!
  • 37. Blood has 50 balls of halothane/ml Gas has 20 balls of halothane / ml Halothane blood / gas partition coefficient = 2.5 No net diffusion when partial pressures are equal.
  • 38. Blood has 8 balls / ml desflurane Gaseous desflurane has 20 balls /ml Desflurane blood / gas partition coefficient = 0.42 No net diffusion when partial pressures are equal.
  • 39.  Higher solubility (λB/G>1)= more agent in the blood and less in the gas phase.  A lower solubility (λB/G<1)= less agent in the blood and more in the gas phase.  Other partition coefficients: -Brain:Blood, Muscle:Blood, Fat:Blood (describe movement of gas from one environment to another)
  • 40. Blood-Gas Brain- Blood Liver- Blood Kidney- Blood Muscle- Blood Fat- Blood Desflurane 0.42 1.3 1.4 1.0 2.0 27 Nitrous oxide 0.47 1.1 0.8 — 1.2 2.3 Sevoflurane 0.65 1.7 1.8 1.2 3.1 48 Isoflurane 1.17 1.6 1.8 1.2 2.9 45 Enflurane 1.8 1.4 2.1 — 1.7 36 Halothane 2.4 1.9 2.1 1.2 3.4 51 Diethyl ether 12 2.0 1.9 0.9 1.3 5 Methoxyfluran e 15 1.4 2.0 0.9 1.6 38 PARTITION CO-EFFICIENT
  • 41. The more soluble the anesthetic The more drug will be taken up by the blood The slower the rise in alveolar concentration 15 1.4 0.65 0.47 Poor solubility Rapid induction High solubility Slow induction
  • 42. Greater the cardiac output The more drug will be taken up by the blood The slower the rise in alveolar concentration Cardiac output is lowered cerebral circulation less maintained (shock) Induction Induction slower rapid
  • 43. An increase in CO from 2 to 18 L/min will decrease the alveolar anesthetic concentration by augmenting uptake, thereby slowing the rise of the FA/FI ratio. B.Cardiac Output(Perfusion Effects) More soluble anesthetics (halothane) - effect is more prominent Positive feedback - as inspired concentration increases, greater cardiovascular depression reduces anesthetic uptake and actually increases the rate of rise of FA/FI.
  • 44. The difference between partial pressure in the alveoli and that in venous blood Partial pressure in venous blood depends on tissue uptake of anesthetic At equilibrium, (no tissue uptake) The venous partial pressure = arterial partial pressure = alveolar partial pressure PA – PV = 0 Rate of rise of the mixed venous concentration depends on the tissue uptake of the anesthetic
  • 45. AT EQUILIBRIUM Notissueuptake PA PV PA – PV = 0 PA = PV FA/FI FAT VRG MG 4-8mts 2-6Hrs 3-4 days
  • 46. 1. The tissue/blood partition coefficient (tissue solubility) 2. The tissue blood flow. 3. The tissue anesthetic concentration Tissue Uptake = Tissue solubility x Tissue blood flow x [Parterial - PTissue] Atmospheric pressure
  • 47. Gas Blood Tissue Concentrations Equilibirates Partial pressure Equalize CG =CB = CT PG = PB = PT Equal volume
  • 48. Brain has 19 balls halothane / ml Blood has 10 balls halothane / ml Halothane brain / blood partition coefficient = 1.9 No net diffusion when partial pressures are equal.
  • 49. Brain has 11 balls N2O / ml Blood has 10 balls N2O / ml N2O brain / blood partition coefficient = 1.1 No net diffusion when partial pressures are equal.
  • 50. Blood-Gas Brain- Blood Liver- Blood Kidney- Blood Muscle- Blood Fat- Blood Desflurane 0.42 1.3 1.4 1.0 2.0 27 Nitrous oxide 0.47 1.1 0.8 — 1.2 2.3 Sevoflurane 0.65 1.7 1.8 1.2 3.1 48 Isoflurane 1.17 1.6 1.8 1.2 2.9 45 Enflurane 1.8 1.4 2.1 — 1.7 36 Halothane 2.4 1.9 2.1 1.2 3.4 51 Diethyl ether 12 2.0 1.9 0.9 1.3 5 Methoxyfluran e 15 1.4 2.0 0.9 1.6 38 PARTITION CO-EFFICIENT
  • 51. The rate of rise in tissue anesthetic concentration is proportional to tissue blood flow and inversely proportional to the tissue capacity. The tissue capacity = tissue solubility х tissue volume Just as discussed for the lungs, the tissues have a time constant too: Time Constant = Tissue solubility x Volume Flow
  • 52.
  • 53. Equilibration of the VRG complete in 4 to 8 minutes After 8 minutes, the Muscle group (MG) determines most of uptake. Once MG equilibration is complete Fat group (FG) determines the uptake
  • 54. Two important characteristics of Inhalational anesthetics which govern the anesthesia are : Solubility in the blood (blood : gas partition co-efficient) Solubility in the fat (oil : gas partition co-efficient)
  • 55.  It indicates the amount of gas that is soluble in oil phase.  It is a measure of lipid solubility of anesthetic.  It is a measure of anesthetic potency Higher the lipid solubility – potent anesthetic. (e.g., halothane)
  • 56. Meyer – Overton Rule Anesthetic potency correlates with lipid solubility Holds true across species Because inhalation agents act through the lipid-rich CNS cells, anesthetic potency increases with lipid solubility.
  • 57. OIL GAS PARTITION CO-EFFICIENT Higher the Oil: Gas Partition Co-efficient lower the MAC . E.g., Halothane 1.4 220 0.8
  • 58. Inhalation Anesthetic MAC value % Oil:Gas partition Co Nitrous oxide 104 1.4 Desflurane 6.6 19 Sevoflurane 1.8 47 Isoflurane 1.17 91 Halothane 0.75 220 Oil:Gas Partition Co-efficient and MAC
  • 59.  At EQ:PA(alveoli)= Pblood =PCNS Rapid transfer of gases: alveoli > blood > CNS  F is proportional to P, so 1% SEV in the alveoli = 1% SEV in the CNS At EQ, if you know PA of a gas, then you know PCNS
  • 60. Recovery from anesthesia, like induction, depends on:  anesthetic solubility- is the primary determinant of the rate of fall of FA  cardiac output  minute ventilation Loss of inhaled anesthetics via skin, gastrointestinal viscera and the pleura are insignificant
  • 61. The greater the solubility of inhaled anesthetic, the larger the capacity for absorption in the bloodstream and tissues.
  • 62.  The “reservoir” of anesthetic in the body at the end of administration depends on: 1. Tissue solubility (which determines the capacity) 2. The dose 3. Duration of anesthetic (which determine how much of that capacity is filled). Low solubility→Rapid recovery Desflurane>Sevoflurane>Isoflurane
  • 63. Recovery from anesthesia, or “washout,” is usually expressed as the ratio of expired fractional concentration of anesthetic (FA) to the expired concentration at time zero (FA0) when the anesthetic was discontinued (or FA/FA0). During the 120-minute period after ending the anesthetic delivery, the elimination of sevoflurane and desflurane is 2 to 2.5 times faster than isoflurane or halothane
  • 64. The longer the duration of a highly soluble anesthetic, the greater the reservoir of anesthetic in the body, and the higher the curve seen in the right half( slow recovery)
  • 65. INDUCTION RECOVERY Induction can be accelerated by Over Pressure( which offset solubility and uptake) The inspired concentration cannot be reduced below zero All the tissues initially have the same anesthetic partial pressure—zero On recovery, the tissue partial pressures are variable 100% 60% 10% 0% Recovery
  • 66.  As long as an arterial-to-tissue partial pressure gradient exists, muscle and fat will absorb anesthetic(especially fat).  After discontinuation of anesthesia, muscle and fat may continue to absorb anesthetic, even hours later.  The redistribution continues until blood/alveolar anesthetic partial pressure falls below tissue partial pressure.
  • 67. 1. Increased solubility slows recovery 2. Increasing ventilation may help the recovery from potent agents 3. Prolonged anesthesia delays recovery 4. There is no concentration effect on emergence
  • 68. Diffusion hypoxia Also called as Fink effect. Alveolar hypoxia can cause hypoxemia, and alveolar hypocarbia can depress respiratory drive, which may exacerbate hypoxemia N2O N- 79% O2-21%O2-21% N- 79% N2O O2-16% N-70% N2O-14% PULMONARY CAPILLARY
  • 69.  MAC - is the alveolar concentration of an anesthetic at 1 atm that prevents movement in response to a surgical stimulus in 50% of patients.  Analogous to the ED50 expressed for intravenous drugs.  MAC value is a measure of inhalational anesthetic potency.
  • 70. AGENT MAC POTENCY Methoxy-flurane 0.16% Most potent Halothane 0.74% Isoflurane 1.17% Enflurane 1.7% Sevoflurane 2.05% Desflurane 6.0% Nitrous oxide 104% Least potent The lower the MAC– the more potent the agent!
  • 71. Standard MAC values are roughly additive !!! Administering 0.5 MAC of a potent agent and 0.5 MAC of nitrous oxide is equivalent to 1 MAC of potent agent. MAC effects for other response parameters are not necessarily additive !!! Combining 0.6 MAC of nitrous oxide with 0.6 MAC of isoflurane produces less hypotension than 1.2 MAC of isoflurane alone.
  • 72. MAC awake: MAC allowing voluntary response to command in 50% of patients(0.15 – 0.5 MAC) MAC 95%: MAC that prevents movement in 95 % of patients (1.2-1.3 MAC or +25% of MAC) MAC intubation: MAC that allows intubation without muscle relaxant, coughing or bucking in 50% of patients. MAC-BAR (1.7-2.MAC or +50% of stand. MAC), which is the concentration required to block autonomic reflexes to nociceptive stimuli.
  • 73. MAC in Subjects Ages 30 to 60 Inhaled Anesthetics In O2 60%-70% N2O MACAWAKE MAC BAR Desflurane 6.6% 2.83% 2.42% 1.45 MAC Sevoflurane 1.8% 0.66% 0.61% 2.24 MAC Isoflurane 1.17% 0.56% 0.39% 1.30 MAC Halothane 0.75% 0.29% 0.41% 1.30 MAC
  • 74.
  • 75. MAC decreases with age - 6% per decade (similar between agents) MAC- is maximum at 6 months
  • 76.  Duration of inhaled anesth. administration  Gender  Type of surgical stimulation  Thyroid function  Hypo- or hypercarbia  Metabolic alkalosis  Hyperkalemia  And magnesium levels Red-haired females have a 19% increase in MAC compared with dark-haired females. These data suggest involvement of mutations of the MCIR(melanocyte stimulating hormone receptor) allele.
  • 77.
  • 78. Classification of inhalational anaesthetics Outdated Gases Volatile agents  Ether  trilene Methoxyflurane Cyclopropane  chloroform  Nitrous oxide  Xenon  Halothane  Enflurane  Isoflurane  Sevoflurane  Desflurane
  • 79. Structural activity-relationship 2-chloro,bromo 1-trifluro ethane. Methyl –isopropyl ether. 2-fluro,1-trifluro methyl ethyl ether. 2-chloro 1-trifluro methyl-ethyl ether. 1-chloro ,fluro 2-difluro methyl- ethyl ether.
  • 80.  All agents cause CBF, causing ICP(especially Halothane) and impair autoregulation of vascular tone( least with sefoflurane at<1MAC)  Volatile agents cerebral metabolic rate, N2O may  Desflurane and isoflurane at < 1 MAC can suppress status epilepticus while sevoflurane concentrations associated whith epileptiform EEG.  All agents SEP/MEP signals.(sensory-evoked potentials and motor-evoked potentials (MEPs).  All agents decreases CMRO2 : Desflurane=Isoflurane=Sevoflurane>Halothane
  • 81.  Cerebral Metabolic Rate and Electroencephalogram EEG an isoelectric-no further decreases in CMR are generate, however: Desflurane-induced isoelectric EEG reverts to continuous activity with time, despite an unchanging MAC, a property unique to Desflurane All of the potent agents depress CMR to varying degrees !!!
  • 82.  Isoflurane abolishes EEG activity at doses used clinically, while Sevoflurane and Desflurane at 2 MAC  Desflurane and Isoflurane at < 1 MAC can suppress status epilepticus while Sevoflurane concentrations associated whith epileptiform EEG.
  • 83. All of the potent agents increase CBF in a time- dependent as well as dose-dependent manner !!! Desflurane=Isoflurane=Sevoflurane<Halothane The increase in CBF with increasing dose caused by the potent agents occurs despite decreases in CMR - cerebral uncoupling . ↓CMR→ vasoconstrictia (physiologicly), with VA vasodilatory effect
  • 84. Because the volatile anesthetics are direct vasodilators, all are considered to diminish autoregulation in a dose-dependent fashion. Sevoflurane preserves autoregulation up to approx.1MAC. At 1.5 MAC sevoflurane preserves better than isoflurane(This may be a result of less of a direct vasodilator effect of sevoflurane). 0.5 MAC desflurane reduced autoregulation and isoflurane did not. At 1.5 MAC, both anesthetics substantially reduced autoregulation.
  • 85.  Significant hypercapnia is associated with dramatic increases in CBF whether or not volatile anesthetics are administered.  Hypocapnia can blunt or abolish volatile anesthetic-induced increases in CBF depending on when the hypocapnia is produced.
  • 86. The increase in CBF→ ↑ICP Isoflurane, sevoflurane and desflurane >1 MAC produce mild increases in ICP, paralleling their mild increases in CBF. All three potent agents may be used at appropriate doses, especially with adjunctive and compensatory therapies, in just about any neurosurgical procedure.
  • 87.  Isoflurane does not appear to alter CSF production, but may increase, decrease, or leave unchanged the resistance to resorption depending on dose.  Sevoflurane at 1 MAC depresses CSF production up to 40%.  Desflurane at 1 MAC leaves CSF production unchanged or increased. In general, anesthetic effects on ICP via changes in CSF dynamics are clinically far less important than anesthetic effects on CBF.
  • 88. A common effect of the potent volatile anesthetics has been a dose-related decrease in arterial blood pressure Primary mechanism to decrease blood pressure with increasing dose is lowering regional and systemic vascular resistance. Sevoflurane up to about 1 MAC results in minimal, if any, changes in steady-state heart rate while enflurane, isoflurane, and desflurane increase it 5 to 10% from baseline
  • 89. Isoflurane, desflurane, and sevoflurane resulted in a dose-dependent depression of myocardial function with no differences between the three anesthetics. Despite the small reduction in baseline contractility, the volative anesthetics did not affect the ability of the myocardium to respond to an acute increase in cardiac preload.
  • 90.  Most of the volatile anesthetics have been studied during both controlled and spontaneous ventilation.  Spontaneous ventilation(SV) reduces the high intrathoracic pressures from positive pressure ventilation.  The negative intrathoracic pressure during the inspiratory phase of spontaneous ventilation augments venous return and cardiac filling and improves cardiac output and, hence, blood pressure.
  • 91.  SV is associated with higher PaCO2, causing cerebral and systemic vascular relaxation. This contributes to an improved cardiac output via afterload reduction.  It has been suggested that spontaneous ventilation might improve the safety of inhaled anesthetic administration because: Concentration of a VA that produces cardiovascular collapse > the conc. that results in apnea.
  • 92.  Oxygen consumption is decreased approximately 10 to 15% during general anesthesia.  The distribution of cardiac output also is altered by anesthesia. Blood flow to liver, kidneys, and gut is decreased, particularly at deep levels of anesthesia. - In contrast, blood flow to the brain, muscle, and skin is increased or not changed.  Sinoatrial node discharge rate is slowed by the volatile anesthetics. Conduction in the His- Purkinje system also is prolonged by the volatile anesthetics.
  • 93.  Isoflurane (and most other potent volatile anesthetics) increases coronary blood flow many times beyond that of the myocardial oxygen demand, thereby creating potential for “steal.”  Steal is the diversion of blood from a myocardial bed with limited or inadequate perfusion to a bed with more adequate perfusion.  Neither isoflurane, sevoflurane, or desflurane at concentrations up to 1.5 MAC cause steal effect.
  • 94.  There are only minor effects on decreasing minute ventilation.  The ventilatory effects are dose-dependent.  Their net effect of a gradual decrease in minute ventilation has been associated with increasing resting Paco2. All volatile anesthetics decrease tidal volume ↓(TV) and increase respiratory rate ↑(RR)
  • 95. Isoflurane does not increase respiratory rate above 1 MAC. N2O increases respiratory rate as much or more than the inhaled anesthetics. Desflurane results in the greatest increase in Paco2 .
  • 96.  In awake humans, changes in arterial CO2 such that minute ventilation increases 3 L/min per a 10-mm Hg increase in Paco2. All inhaled anesthetics produce a dose-dependent depression of the ventilatory response to hypercarbia! The threshold at which breathing stops, called the apneic threshold. It is generally 4 to 5 mm Hg below the prevailing resting Paco2
  • 97. Ing.Anesth., including nitrous oxide, produce a dose- dependent attenuation of the ventilatory response to hypoxia. Has important clinical implications The short-acting sevoflurane and desflurane may prove advantageous - more rapid washout and their minimal effect on hypoxic sensitivity at subanesthetic concentrations.
  • 98. Bronchoconstriction under anesthesia occur:  direct stimulation of the laryngeal and tracheal areas  administration of adjuvant drugs that cause histamine release  noxious stimuli activating vagal afferent nerves The reflex response to these stimuli may be enhanced : - in lightly anesthetized patients - in patients with known reactive airway disease including those requiring bronchodilator therapy - chronic smoking histories.
  • 99.  Bronchoconstriction - via M2 and M3 muscarinic receptors, which initiate increases in intracellular cyclic guanosine monophosphate(cGMP).  Bronchiolar muscle relaxation – adrenergic β2- receptors → an increase in intracellular cyclic adenosine monophosphate(cAMP). The volatile anesthetics relax airway smooth muscle primarily by directly depressing smooth muscle contractility and indirectly inhibiting the reflex neural pathway! Volatile anesthetics have been used effectively to treat status asthmaticus when other conventional treatments have failed! Sevoflurane may be a better choice.
  • 100. Smokers have impaired mucociliary function compared with nonsmokers. and the combination of a volatile anesthetic in a smoker who is mechanically ventilated sets up a scenario for inadequate clearing of secretions, mucus plugging, atelectasis, and hypoxemia. Volatile anesthetics and nitrous oxide reduce ciliary movement and alter the characteristics of mucus.
  • 101. Inadequate hepatocyte oxygenation (oxygen supply relative to oxygen demand) is the principal mechanism responsible for hepatic dysfunction following anesthesia and surgery. The liver has two blood supplies: 1 Hepatic artery(well-oxygenated). 2 Portal vein( poorly oxygenated). Postoperative liver dysfunction has been associated with most volatile anesthetics, with halothane receiving the most attention.
  • 102. HBF-Desflurane=Isoflurane=Sevoflurane<Halothane The ether-based anesthetics (isoflurane, sevoflurane, desflurane) maintain or increase hepatic artery blood flow while decreasing (or not changing) portal vein blood flow. Halothane decreases in both portal vein and hepatic artery blood flow, thereby significantly compromising total hepatic artery blood flow.
  • 103.  Altered liver function tests have been used as an index of hepatic injury during anesthesia.  ALT, AST, GST  Increases in the ALT or AST are not uniquely specific to the liver.  The centrilobular area of the liver is most susceptible to hypoxia.  A more sensitive measure GST(α-glutathione S- transferase), since it is distributed primarily in the centrilobular hepatocytes.
  • 104. The inhaled anesthetics have two important actions on neuromuscular function: 1. Directly relax skeletal muscle(nitrous oxide does not). 2. Potentiate the action of neuromuscular blocking drugs. All of the potent volatile anesthetics serve as triggers for malignant hyperthermia (MH)!!! While N2O is considered safe in MH-susceptible patients!!!
  • 105.  Uterine smooth muscle tone is diminished by volatile anesthetics.  There is a dose-dependent decrease in spontaneous myometrial contractility.  Uterine relaxation/atony can become problematic at concentrations of volatile anesthesia >1 MAC, and might delay the onset time of newborn respiration.  Consequently, a common technique used to provide GA for urgent CS is to administer low concentrations of the VA, such as 0.5 to 0.75 MAC, combined with N20
  • 106. Volatile anesthetics produce similar dose-related decreases in renal blood flow, glomerular filtration rate, and urine output. These changes most likely reflect the effects of volatile anesthetics on systemic blood pressure and cardiac output. Preoperative hydration attenuates or abolishes many of the changes in renal function associated with volatile anesthetics.
  • 107. Physical properties:  It is a laughing gas,colorless and odorless  It is only inorganic anesthetic gas in clinical use.  Non Explosive and Non Inflammable  Gas at room temperature and can be kept as a liquid under pressure.  It is relatively inexpensive.  low potency (MAC = 104%) and is relatively insoluble in blood  Nitrous oxide does not produce significant skeletal muscle relaxation, but it does have analgesic effects.  Elimination: almost 100% exhalation.  It causes post operative Nausea and Vomiting
  • 108.  Oxidizes Co atom in vitamin B12, inactivates methinoine synthetase  Affects myelin formation →peripheral neuropathies, neurotoxicity.  Homocysteine accumulation  Inhibits thymidylate syntetase(DNA syntesis)→teratogenicity.  Bone marrow depression-megaloblastic anemia
  • 109.  Air embolism  Pneumothorax  Acute Intestinal Obstruction  Tension Pneumocephalus  Tympanic membrane grafting 75% nitrous oxide can expand a pneumo- thorax to double or triple its size in 10 and 30 minutes!!!
  • 110.  Physical Properties:  It is halogenated alkene.  Sweet, non-pungent.  Non Inflammable and Non explosive.  Least expensive .
  • 111.  CV: myocardial depression - ↓BP and CO by up to 50% - causes slowing of SA node conduction resulting in bradycardia  Resp: ↑RR, ↓↓TV, ↓MV, ↓↓hypercapnic drive, potent bronchodilator.  CEREBRAL: It increases cerebral blood flow.  NEUROMUSCULAR: Relaxes skelatal muscle and potentiates Non depolarizing neuro-muscular blocking agents.  RENAL: Reduces renal blood flow, glomerular filtration rate and urinary output.
  • 112.  Hepatic ↓hepatic blood flow: impaired hepatic drug clearance. -Liver oxidation→trifluoroacetic acid(TFA) - 20% metabolised - 1in 5 adults hepatotoxicity(lethargy, nausea,fever) likely related to changes in HBF. -”Halothane hepatitis”(rare): massive hepatic necrosis. likely immune mechanism(eosinophilia, rash, fever)  Contraindications:  Unexplained liver dysfunction.  Intra-cranial mass lesions.  Hypovolemic patient with severe cardiac diseases
  • 113.  Isoflurane is a halogenated methyl ethyl ether  Clear, nonflammable liquid at room temperature.  Has a high degree of pungency.  It has become the “gold standard” anesthetic since its introduction in the 1970s  Contraindications:  No such contraindication.  Patient with severe hypovolemia may not tolorate its vasodilating effects. It is the most potent of the volatile anesthetics in clinical use.
  • 114.  Sevoflurane is a sweet-smelling, completely fluorinated methyl isopropyl ether  Non-pungent, low solubility- exellent for inhalation induction  +muscle relaxation(enough for peds intubation) potentiates NMBA.  Elimination: -5%-liver metabolism  BaOH, soda lime- Compound A -nephrotoxic in rats -but has not been associated with renal injury in human volunteers or patients, with or without renal impairment, even when fresh gas flows are 1 L/min or less.
  • 115.  Very similar to Isoflurane in structure but much less soluble, less potent.  Very high vapor pressure - requires special vaporizer. - can boil at normal OR temperature. - special vaporizer heats it to a gas and then blends it with the FGF. Desflurane is the most pungent of the VA !!! and if administered via the face mask results in: coughing,salivation,breath holding,and laryngospasm. Desflurane has the lowest blood:gas solubility of the potent VA
  • 116.  Is an inert gas, difficult to obtain, and hence extremely expensive.  It has many characteristics approaching those of an “ideal” inhaled anesthetic.  Nonexplosive, nonpungent, and odorless, and thus can be inhaled with ease.  Its blood:gas partition coefficient is 0.14, and unlike the other potent VA , xenon provides some degree of analgesia.  Does not produce significant myocardial depression.  Because of its scarcity and high cost, new anesthetic systems need to be developed to provide for recycling of xenon.
  • 117.
  • 118. Differential Physiologic Effects of Inhaled Anesthetics N2O Halothane Isoflurane Sevoflurane Desflurane HR or or SVR CO or or Contractility HBF HBF- hepatic blood flow, HR- heart rate, CO-cardiac output, SVR-systemic vascular resist., and -slight or mild change, - significant decrease, - no change.